We are diligently observing the healthcare innovation and regulatory space in Europe: IQVIA‘s recently released pipeline review suggests that industry continues to invest heavily in innovation, and the clinical trials space has started growing again after the COVID dip, especially in the area of cancer research.
Interestingly, in 2021 40% of the oncology pipeline was still in Phase 1, and further innovation is anticipated. This is reflected in the amount of initiatives that healthcare authorities are launching to keep their processes fit for purpose to meet the demand for increased adoption of new clinical research technology.
Read more: IQVIA/EFPIA Pipeline Review 2021
